Open Access
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 10, Octobre 2019
|
|
|---|---|---|
| Page(s) | 728 - 731 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/2019148 | |
| Publié en ligne | 18 octobre 2019 | |
- Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017 ;355 :1152–1158. [Google Scholar]
- Postel-Vinay S, Bajrami I, Friboulet L, et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 2013 ;32 :5377–5387. [Google Scholar]
- Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018 ;4 :1543–1552. [CrossRef] [PubMed] [Google Scholar]
- Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018 ;378 :2078–2092. [Google Scholar]
- Chabanon RM, Pedrero M, Lefebvre C, et al. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 2016 ;22 :4309–4321. [CrossRef] [PubMed] [Google Scholar]
- Parkes EE, Walker SM, Taggart LE, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst 2017 ;109. [Google Scholar]
- Chabanon RM, Muirhead G, Krastev DB, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 2019 ;129 :1211–1228. [CrossRef] [PubMed] [Google Scholar]
- Harding SM, Benci JL, Irianto J, et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 2017 ;548 :466–470. [CrossRef] [PubMed] [Google Scholar]
- Ding L, Kim HJ, Wang Q, et al. PARP Inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer. Cell Rep 2018 ;25(2972–80) :e5. [Google Scholar]
- Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res 2019 ;79 :311–319. [Google Scholar]
- Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov 2019 ;9 :646–661. [CrossRef] [PubMed] [Google Scholar]
- Pantelidou C, Sonzogni O, De Oliveria Taveira M, et al. PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 2019 ;9 :722–737. [CrossRef] [PubMed] [Google Scholar]
- Chanut R, Petrilli V. Détection de l’ADN cytosolique par la voie cGAS-STING : de l’immunité innée vers le contrôle de la tumorigenèse. Med Sci (Paris) 2019 ;35 :527–534. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.